Literature DB >> 23131340

Development of sub-nanomolar dipeptidic ligands of neuropeptide FF receptors.

Ronan Gealageas1, Séverine Schneider, Jean-Paul Humbert, Isabelle Bertin, Martine Schmitt, Emilie Laboureyras, Christophe Dugave, Catherine Mollereau, Guy Simonnet, Jean-Jacques Bourguignon, Frédéric Simonin, Frédéric Bihel.   

Abstract

Based on our earlier reported neuropeptide FF receptors antagonist (RF9), we carried out an extensive structural exploration of the N-terminus part of the amidated dipeptide Arg-Phe-NH(2) in order to establish a structure-activity relationships (SAR) study towards both NPFF receptor subtypes. This SAR led to the discovery of dipeptides (12, 35) with subnanomolar affinities towards NPFF1 receptor subtype, similar to endogenous ligand NPVF. More particularly, compound 12 exhibited a potent in vivo preventive effect on opioid-induced hyperalgesia at low dose. The significant selectivity of 12 toward NPFF1-R indicates that this receptor subtype may play a critical role in the anti-opioid activity of NPFF-like peptides.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23131340     DOI: 10.1016/j.bmcl.2012.10.049

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists.

Authors:  Thuy Nguyen; Ann M Decker; Tiffany L Langston; Kelly M Mathews; Justin N Siemian; Jun-Xu Li; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-08-09       Impact factor: 4.418

2.  Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.

Authors:  V Blair Journigan; Christophe Mésangeau; Neha Vyas; Shainnel O Eans; Stephen J Cutler; Jay P McLaughlin; Catherine Mollereau; Christopher R McCurdy
Journal:  J Med Chem       Date:  2014-10-21       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.